Literature DB >> 2936812

Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes.

S Miescher, T L Whiteside, S Carrel, V von Fliedner.   

Abstract

Tumor-infiltrating lymphocytes (TIL) were obtained from 22 humans with solid tumors. In three cases only, one colon and two lung carcinomas, TIL which contained from 3 to 10% of T cells expressing the interleukin 2 receptor (IL 2R) were obtained, and these proliferated in the presence of exogenous IL 2. In most TIL preparations, however, the T lymphocytes did not express the IL 2R and failed to proliferate in response to IL 2. In contrast, TIL were able to proliferate in response to irradiated allogeneic spleen cells in mixed lymphocyte culture. Proliferative responses of autologous PBL were not inhibited by the addition of TIL. In most tumors, the TIL showed no response or had significantly lower (p less than 0.01) responses to PHA, Con A, and the phorbol ester TPA than did autologous peripheral blood lymphocytes (PBL). A limiting-dilution microculture system which allows clonal growth of every T cell was used to demonstrate decreased responses of the TIL to PHA at a single-cell level. In contrast to normal PBL-T with proliferating frequencies from 0.46 to 1.0, those for T cells in three TIL preparations were zero, 0.005, and 0.01. Normal PBL exposed in vitro to tumor cells or their supernatants lost the ability to respond to mitogens and to clone normally (e.g., proliferating frequency of 0.147 vs 0.863 in control). The TIL isolated from solid tumors resemble normal PBL exposed in vitro to tumor cells or their supernatants in terms of decreased responses to mitogens and poor clonogenicity in the PHA-dependent microculture system. It is possible that tumor cells may inhibit certain functions of the TIL in human solid tumors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2936812

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  78 in total

1.  Liver transplantation for diethylnitrosamine-induced hepatocellular carcinoma in rats.

Authors:  T Matsuzaki; N Murase; A Yagihashi; H Shinozuka; Y Shimizu; T Furuya; N Burrell; S Iwatsuki; T E Starzl
Journal:  Transplant Proc       Date:  1992-04       Impact factor: 1.066

2.  TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors.

Authors:  Yang Liu; Qing Wang; B K Kleinschmidt-DeMasters; Alex Franzusoff; Ka-yun Ng; Kevin O Lillehei
Journal:  J Neurooncol       Date:  2006-08-29       Impact factor: 4.130

3.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

4.  Apoptosis of lymphocytes in peripheral blood of patients with melanoma.

Authors:  Faruk Tas; Derya Duranyildiz; Andac Argon; Hilal Oguz; Hakan Camlica; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

5.  Myelopeptide-5 is a novel endogenous immunoregulator recovering the functional activity of T-lymphocytes.

Authors:  R G Belevskaya; M V Kalyuzhnaya; L A Fonina; A A Mikhailova; R V Petrov
Journal:  Dokl Biol Sci       Date:  2007 Sep-Oct

Review 6.  [Role of the spleen in tumor surgery].

Authors:  U Wolters; H W Keller; H Pichlmaier
Journal:  Langenbecks Arch Chir       Date:  1991

7.  TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity.

Authors:  E A Grimm; W L Crump; A Durett; J P Hester; S Lagoo-Deenadalayan; L B Owen-Schaub
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  Lymphocytes infiltrating colorectal cancer have low proliferative capacity but can secrete normal levels of interferon gamma.

Authors:  W J Bateman; I Donnellan; I A Fraser; L S Wong; A G Morris
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

9.  Human recombinant IL-4 decreases the emergence of non-specific cytolytic cells and favours the appearance of memory cells (CD4+CD45RO+) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumour cells.

Authors:  A D Roth; S Dupuis; P Alberto
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

10.  In situ cytokine production by breast cancer tumor-infiltrating lymphocytes.

Authors:  B J Camp; S T Dyhrman; V A Memoli; L A Mott; R J Barth
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.